Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of FSGS.~* Patients with a proteinuria ≥ 3.5g/24h,and blood albumin \<30g/L,and Scr\< 2.3 mg/dl and eGFR\>30ml/min per 1.73m2.~* Patients who signed written informed consent form (patients less than 18 years old with their parents/legal representative's signatures), and have given their consent to follow all study procedures and follow-up.~Exclusion Criteria:~* Patients who have received treatment of FK506 in latest 2 month or the cumulative dose CTX≥6 g.~* Patients who are known to be allergic to a macrolide.~* Patients who have active hepatitis.~* Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit .~* Patients with blood leukocyte \< 3000/ul.~* Patients with kidney disease family history~* Patients with 2 type diabetes.~* Patients with obesity whose BMI\>28kg/m2.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: ACTIVE_COMPARATOR): CTX
- FK506 (Type: EXPERIMENTAL): 0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).